The global hypoparathyroidism market size is expected to be worth USD 787.4 Million in 2025. It can reach a valuation of USD 1,323.4 Million by 2032. The market is anticipated to peak at a CAGR of 7.7% during the forecast period (2025-2032).
The surge in the cases of hypoparathyroidism or hypopara due to anterior neck surgeries, advances in parathyroid hormone (PTH) surgeries, and focus on drug development by pharmaceutical manufacturers can drive the market growth.
However, the high costs of drugs for the treatment of hypoparathyroidism and inaccessibility to medicines in low-income countries can impede the market growth.
Key Market Insights
The hypoparathyroidism market is anticipated to expand owing to accurate assays for the assessment of PTH levels, advances in PTH-based therapies, and the acquisition of companies to enhance the product pipeline.
The full report is now available for purchase: https://www.coherentmi.com/industry-reports/hypoparathyroidism-market
Hypoparathyroidism Market Report Coverage
|
Report Coverage |
Details |
|
Market Revenue in 2025 |
USD 787.4 Million |
|
Estimated Value by 2032 |
USD 1,323.4 Million |
|
Growth Rate |
7.7% |
|
Historical Data |
2020–2024 |
|
Forecast Period |
2025–2032 |
|
Forecast Units |
Value (USD Million) |
|
Report Coverage |
Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
|
Segments Covered |
|
|
Geographies Covered |
North America (U.S. and Canada), Latin America (Brazil, Argentina, Mexico, and Rest of Latin America), Europe (Italy, Spain, U.K., Germany, France, Russia, and Rest of Europe), Asia Pacific (China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific), Middle East (GCC Countries, Israel, and Rest of Middle East), and Africa (South Africa, North Africa, and Central Africa) |
|
Growth Drivers |
|
|
Opportunities |
|
|
Trends |
|
|
Restraints & Challenges |
|
Market Dynamics
The hypoparathyroidism market growth is driven by the number of clinical trials under development for keeping PTH levels in check. The large number of hypoparathyroidism cases caused by non-surgical etiologies can facilitate the market growth. On March 17, 2025, the Calypso Phase-III trial by AstraZeneca displayed the high potential of eneboparatide (AZP-3601). The trial demonstrated the continuous effectiveness of taking the drug, which restored calcium levels to normal without dependency on calcium supplements. This can bode well for the market and lead to the development of generics in low-income countries with collaborations.
The approval of Yorvipath by Ascendis Pharma and the buyout of biopharmaceutical startups by major companies can drive the market growth. Early approval of drugs can lead to higher funding in research and development of endocrine disorders and help patients in the long run. Fast-track approvals by the European Medicine Agency and the U.S. FDA can widen the clinical space for research.
Market Opportunity: Innovation in Drug Delivery Pipeline
The rise of next-generation drug delivery systems like long-acting PTH analogs and gene therapy treatments can shape the market in the forthcoming years. AI-powered planning and remote calcium monitoring applications that redefine standard management protocols can bode well for the market.
Market Challenge: Product Recall by Regulatory Agencies to be a Hurdle
The recall of NATPARA by the U.S. FDA in 2019 due to the presence of rubber particulates in the drug created hesitation among patients and led to growth hurdles. Manufacturing issues, coupled with injection problems, also added to the problem and left patients in limbo. However, the approval of drugs has given patients hope and revived the growth of the market.
Analyst’s View
Recent Developments
Ascendis Pharma announced the Phase 3 PaTHway Trial of the long-term treatment with TransCon PTH (palopegteriparatide) on July 14, 2025. The trial in its 26th week continued to show reliable assessments of the drug and improvements in quality of life.
Competitor Insights
Market Segmentation
Regional Insights
Related Reports :